Q1 Earnings Surge: Novo Nordisk delivered Q1 results that surpassed Wall Street expectations, posting net sales of $15.2 billion compared to forecasts of $11.2 billion, largely due to a $4.2 billion 340B provision reversal. Social media buzz centered on the standout Wegovy pill performance, with sales hitting $354 million against estimates of $182 million, signaling strong early adoption.
Wegovy Pill Adoption: Over two million prescriptions have been filled since the pill's January launch, with weekly figures exceeding 200,000 by mid-April. Executives highlighted minimal cannibalization from injectables and partnerships driving new patient inflows, prompting a slight raise in full-year guidance for adjusted sales and operating profit.
Pricing Headwinds Linger: Beneath the headline beats, adjusted sales fell 4% at constant exchange rates amid U.S. pricing erosion from the Most Favored Nations agreement. Debates on social media weighed volume gains against competitive pressures and patent risks, with some viewing the stock's pullback as an entry point for long-term growth.
Note: This discussion summary was generated from an AI condensation of post data.
Novo Nordisk Revenue
Novo Nordisk had revenues of $15B in Q1 2026.
You can track NVO financials on Quiver Quantitative's NVO stock page.
Novo Nordisk Hedge Fund Activity
We have seen 542 institutional investors add shares of Novo Nordisk stock to their portfolio, and 833 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS removed 6,502,318 shares (-36.7%) from their portfolio in Q4 2025, for an estimated $330,837,939
- PRICE T ROWE ASSOCIATES INC /MD/ added 4,836,285 shares (+99.7%) to their portfolio in Q4 2025, for an estimated $246,070,180
- VOLORIDGE INVESTMENT MANAGEMENT, LLC added 4,302,126 shares (+851.6%) to their portfolio in Q4 2025, for an estimated $218,892,170
- CITADEL ADVISORS LLC added 4,278,889 shares (+136.6%) to their portfolio in Q4 2025, for an estimated $217,709,872
- FMR LLC removed 4,058,066 shares (-28.8%) from their portfolio in Q4 2025, for an estimated $206,474,398
- FAYEZ SAROFIM & CO removed 3,118,838 shares (-42.4%) from their portfolio in Q4 2025, for an estimated $158,686,477
- DAVENPORT & CO LLC removed 2,122,035 shares (-96.2%) from their portfolio in Q1 2026, for an estimated $76,085,564
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Novo Nordisk Analyst Ratings
Wall Street analysts have issued reports on $NVO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Goldman Sachs issued a "Buy" rating on 11/28/2025
To track analyst ratings and price targets for Novo Nordisk, check out Quiver Quantitative's $NVO forecast page.
Novo Nordisk Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 3 analysts offer price targets for $NVO in the last 6 months, with a median target of $46.0.
Here are some recent targets:
- James Quigley from Goldman Sachs set a target price of $41.0 on 03/02/2026
- An analyst from CICC set a target price of $73.5 on 01/09/2026
- Evan David Seigerman from BMO Capital set a target price of $46.0 on 11/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
